Management Team - Antibe Therapeutics

Meet our Management Team

Antibe’s senior team is based in Toronto, Canada. We are supported by a global network of advisors and subject matter experts covering scientific, clinical and regulatory affairs, and business development.

With his broad capital markets experience informed by academic training in life sciences and computer engineering, Scott brings a unique perspective to growing and funding healthcare companies. His interest in the sector was sparked by the Human Genome Project, leading to his studies in biomedical computing.

Prior to Antibe, he was an investment banking professional with Bloom Burton & Co., a leading healthcare-focused investment dealer and advisory firm. Scott was also an Equity Research Analyst at Cantor Fitzgerald Canada where his coverage included Specialty Pharma.

General Management Program Harvard Business School, USA

MEng Computer Engineering University of Toronto, Canada
BComp Biomedical Computing Queen’s University, Canada

CFA® Charterholder (Chartered Financial Analyst)
CFA Institute

“What struck me about Antibe from the beginning was that they were targeting a massive medical problem with a disruptive, best-in-class technology.”

Joseph Stauffer DO, MBA, FAPCR
VP CLINICAL DEVELOPMENT

Following his medical training, Dr. Joseph (“Joe”) Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (FDA) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director.

Over the succeeding years, Joe led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than $250 million for Cara Therapeutics, a developer of novel chemical entities to treat post-operative pain and chronic itch in Chronic Kidney Disease (CKD).

DO Philadelphia College of Osteopathic Medicine, USA

Anesthesiology Residency The Johns Hopkins University School of Medicine, University Hospital, USA

MBA New York University, USA; London School of Economics, UK; Hautes Etudes Commerciales, France

Fellow
Academy of Physicians in Clinical Research

Member
American Medical Association
American Society of Anesthesiologists

College on Problems of Drug Dependence
Johns Hopkins Medical & Surgical Association

Joe is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (“IMMPACT”), which became an official public-private partnership between pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the US.

“Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development.”

David Vaughan PhD
VP CLINICAL SCIENCE

As a scientist and drug development executive, David has extensive experience in bringing drugs from early investigation to regulatory approval. Acting as a product development consultant for several major pharmaceutical firms, he has advanced treatments for bacterial infections and disorders of the central nervous and gastrointestinal systems.

David headed the Clinical Anti-infectives Unit for Bayer Inc. He also served as Vice President, Pharmaceutical Business Unit for Focus Technologies USA; Vice President, Preclinical Development for Affinium Pharmaceuticals; and Vice President, Preclinical Development for NeurAxon.

PhD Clinical Pathology and Biochemistry University of Toronto, Canada

“I value the opportunity to develop a platform validating, novel NSAID—a drug that can improve the quality of life for so many people suffering from pain.”